A minimális reziduális betegség kimutatása B-sejtes tumorok esetében az immunglobulin nehézlánc génre specifikus polimeráz láncreakció segítségével.

Translated title of the contribution: Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene

A. Matolcsy, Z. Borbényi, J. Demeter, M. Egyed, S. Fekete, J. Földi, L. Gergely, P. Kajtár, G. Kelényi, A. Kiss, T. László, D. Lehoczky, H. Losonczy, M. Nagy, K. Pál, K. Pálóczy, G. Radványi, I. Semsei, G. Varga, M. Udvardy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In B-cell non-Hodgkin's lymphomas (NHL), clonal rearrangement of the immunoglobulin heavy chain (IgH) gene provides a useful marker for the detection of minimal residual disease (MRD) after treatment. To explore clinical usefulness of polymerase chain reaction (PCR) analysis of clonal IgH gene rearrangement in the detection of MRD a follow up study of 10 patients with B-cell NHL have been performed. At the time of diagnosis, tumor DNAs were PCR-amplified using sense primer specific for the heavy chain variable region (VH) and antisense primer specific for the heavy chain joining region (JH) of the IgH gene. The clonal rearrangement of IgH gene detected by PCR was used as clonal marker to determine MRD after treatment. In three cases, where clinical remission was not achieved, clonal IgH gene rearrangement was detected after the treatment. In seven cases, clinical remission was achieved after induction therapy but the PCR analysis revealed clonal IgH gene rearrangement in three of the cases. In all of the three cases, where MRD was detected by PCR, clinical relapse developed after 7-28 months of the therapy. In all cases that have relapsed, the IgH gene rearrangement was identical at the time of initial diagnosis and at the relapse. This study demonstrates that PCR analysis of clonal IgH gene rearrangement is a useful method to monitor and detect MRD before clinical relapse.

Original languageHungarian
Pages (from-to)1403-1406
Number of pages4
JournalOrvosi Hetilap
Volume141
Issue number25
Publication statusPublished - Jun 18 2000

Fingerprint

Immunoglobulin Heavy Chain Genes
Residual Neoplasm
B-Lymphocytes
Gene Rearrangement
Polymerase Chain Reaction
Neoplasms
B-Cell Lymphoma
Recurrence
Non-Hodgkin's Lymphoma
Therapeutics
DNA-Directed DNA Polymerase

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A minimális reziduális betegség kimutatása B-sejtes tumorok esetében az immunglobulin nehézlánc génre specifikus polimeráz láncreakció segítségével. / Matolcsy, A.; Borbényi, Z.; Demeter, J.; Egyed, M.; Fekete, S.; Földi, J.; Gergely, L.; Kajtár, P.; Kelényi, G.; Kiss, A.; László, T.; Lehoczky, D.; Losonczy, H.; Nagy, M.; Pál, K.; Pálóczy, K.; Radványi, G.; Semsei, I.; Varga, G.; Udvardy, M.

In: Orvosi Hetilap, Vol. 141, No. 25, 18.06.2000, p. 1403-1406.

Research output: Contribution to journalArticle

Matolcsy, A, Borbényi, Z, Demeter, J, Egyed, M, Fekete, S, Földi, J, Gergely, L, Kajtár, P, Kelényi, G, Kiss, A, László, T, Lehoczky, D, Losonczy, H, Nagy, M, Pál, K, Pálóczy, K, Radványi, G, Semsei, I, Varga, G & Udvardy, M 2000, 'A minimális reziduális betegség kimutatása B-sejtes tumorok esetében az immunglobulin nehézlánc génre specifikus polimeráz láncreakció segítségével.', Orvosi Hetilap, vol. 141, no. 25, pp. 1403-1406.
Matolcsy, A. ; Borbényi, Z. ; Demeter, J. ; Egyed, M. ; Fekete, S. ; Földi, J. ; Gergely, L. ; Kajtár, P. ; Kelényi, G. ; Kiss, A. ; László, T. ; Lehoczky, D. ; Losonczy, H. ; Nagy, M. ; Pál, K. ; Pálóczy, K. ; Radványi, G. ; Semsei, I. ; Varga, G. ; Udvardy, M. / A minimális reziduális betegség kimutatása B-sejtes tumorok esetében az immunglobulin nehézlánc génre specifikus polimeráz láncreakció segítségével. In: Orvosi Hetilap. 2000 ; Vol. 141, No. 25. pp. 1403-1406.
@article{921ff053606e4d1ba63d9636d19a58fb,
title = "A minim{\'a}lis rezidu{\'a}lis betegs{\'e}g kimutat{\'a}sa B-sejtes tumorok eset{\'e}ben az immunglobulin neh{\'e}zl{\'a}nc g{\'e}nre specifikus polimer{\'a}z l{\'a}ncreakci{\'o} seg{\'i}ts{\'e}g{\'e}vel.",
abstract = "In B-cell non-Hodgkin's lymphomas (NHL), clonal rearrangement of the immunoglobulin heavy chain (IgH) gene provides a useful marker for the detection of minimal residual disease (MRD) after treatment. To explore clinical usefulness of polymerase chain reaction (PCR) analysis of clonal IgH gene rearrangement in the detection of MRD a follow up study of 10 patients with B-cell NHL have been performed. At the time of diagnosis, tumor DNAs were PCR-amplified using sense primer specific for the heavy chain variable region (VH) and antisense primer specific for the heavy chain joining region (JH) of the IgH gene. The clonal rearrangement of IgH gene detected by PCR was used as clonal marker to determine MRD after treatment. In three cases, where clinical remission was not achieved, clonal IgH gene rearrangement was detected after the treatment. In seven cases, clinical remission was achieved after induction therapy but the PCR analysis revealed clonal IgH gene rearrangement in three of the cases. In all of the three cases, where MRD was detected by PCR, clinical relapse developed after 7-28 months of the therapy. In all cases that have relapsed, the IgH gene rearrangement was identical at the time of initial diagnosis and at the relapse. This study demonstrates that PCR analysis of clonal IgH gene rearrangement is a useful method to monitor and detect MRD before clinical relapse.",
author = "A. Matolcsy and Z. Borb{\'e}nyi and J. Demeter and M. Egyed and S. Fekete and J. F{\"o}ldi and L. Gergely and P. Kajt{\'a}r and G. Kel{\'e}nyi and A. Kiss and T. L{\'a}szl{\'o} and D. Lehoczky and H. Losonczy and M. Nagy and K. P{\'a}l and K. P{\'a}l{\'o}czy and G. Radv{\'a}nyi and I. Semsei and G. Varga and M. Udvardy",
year = "2000",
month = "6",
day = "18",
language = "Hungarian",
volume = "141",
pages = "1403--1406",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "25",

}

TY - JOUR

T1 - A minimális reziduális betegség kimutatása B-sejtes tumorok esetében az immunglobulin nehézlánc génre specifikus polimeráz láncreakció segítségével.

AU - Matolcsy, A.

AU - Borbényi, Z.

AU - Demeter, J.

AU - Egyed, M.

AU - Fekete, S.

AU - Földi, J.

AU - Gergely, L.

AU - Kajtár, P.

AU - Kelényi, G.

AU - Kiss, A.

AU - László, T.

AU - Lehoczky, D.

AU - Losonczy, H.

AU - Nagy, M.

AU - Pál, K.

AU - Pálóczy, K.

AU - Radványi, G.

AU - Semsei, I.

AU - Varga, G.

AU - Udvardy, M.

PY - 2000/6/18

Y1 - 2000/6/18

N2 - In B-cell non-Hodgkin's lymphomas (NHL), clonal rearrangement of the immunoglobulin heavy chain (IgH) gene provides a useful marker for the detection of minimal residual disease (MRD) after treatment. To explore clinical usefulness of polymerase chain reaction (PCR) analysis of clonal IgH gene rearrangement in the detection of MRD a follow up study of 10 patients with B-cell NHL have been performed. At the time of diagnosis, tumor DNAs were PCR-amplified using sense primer specific for the heavy chain variable region (VH) and antisense primer specific for the heavy chain joining region (JH) of the IgH gene. The clonal rearrangement of IgH gene detected by PCR was used as clonal marker to determine MRD after treatment. In three cases, where clinical remission was not achieved, clonal IgH gene rearrangement was detected after the treatment. In seven cases, clinical remission was achieved after induction therapy but the PCR analysis revealed clonal IgH gene rearrangement in three of the cases. In all of the three cases, where MRD was detected by PCR, clinical relapse developed after 7-28 months of the therapy. In all cases that have relapsed, the IgH gene rearrangement was identical at the time of initial diagnosis and at the relapse. This study demonstrates that PCR analysis of clonal IgH gene rearrangement is a useful method to monitor and detect MRD before clinical relapse.

AB - In B-cell non-Hodgkin's lymphomas (NHL), clonal rearrangement of the immunoglobulin heavy chain (IgH) gene provides a useful marker for the detection of minimal residual disease (MRD) after treatment. To explore clinical usefulness of polymerase chain reaction (PCR) analysis of clonal IgH gene rearrangement in the detection of MRD a follow up study of 10 patients with B-cell NHL have been performed. At the time of diagnosis, tumor DNAs were PCR-amplified using sense primer specific for the heavy chain variable region (VH) and antisense primer specific for the heavy chain joining region (JH) of the IgH gene. The clonal rearrangement of IgH gene detected by PCR was used as clonal marker to determine MRD after treatment. In three cases, where clinical remission was not achieved, clonal IgH gene rearrangement was detected after the treatment. In seven cases, clinical remission was achieved after induction therapy but the PCR analysis revealed clonal IgH gene rearrangement in three of the cases. In all of the three cases, where MRD was detected by PCR, clinical relapse developed after 7-28 months of the therapy. In all cases that have relapsed, the IgH gene rearrangement was identical at the time of initial diagnosis and at the relapse. This study demonstrates that PCR analysis of clonal IgH gene rearrangement is a useful method to monitor and detect MRD before clinical relapse.

UR - http://www.scopus.com/inward/record.url?scp=0034682421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034682421&partnerID=8YFLogxK

M3 - Article

C2 - 10934884

AN - SCOPUS:0034682421

VL - 141

SP - 1403

EP - 1406

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 25

ER -